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SUMMARY  
Background: Anandamide and sphingosine-1-phosphate (S1P) both regulate 
vascular tone in a variety of vessels.  This study aims to examine the mechanisms 
involved in the regulation of coronary vascular tone by anandamide and S1P, and to 
determine whether any functional interaction occurs between these receptor 
systems.   
Experimental approach:  Mechanisms used by anandamide and S1P to regulate 
rat coronary artery reactivity were investigated using wire myography.  Interactions 
between S1P and the CB2 receptor were determined using HEK293 cells that stably 
over-express recombinant CB2 receptor. 
Key results:  Anandamide and S1P induced relaxation of the rat coronary artery. 
CB2 receptor antagonists attenuated anandamide-induced relaxation, while S1P-
mediated relaxation was dependent on the vascular endothelium and S1P3.  
Anandamide treatment resulted in an increase in the phosphorylation of sphingosine 
kinase-1 within the coronary artery.  Conversely, anandamide-mediated relaxation 
was attenuated by inhibition of sphingosine kinase. Moreover S1P3, specifically 
within the vascular endothelium, was required for anandamide-mediated 
vasorelaxation.  In addition to this, S1P-mediated relaxation was also reduced by 
CB2 receptor antagonists and sphingosine kinase inhibition.  Further evidence that 
S1P functionally interacts with the CB2 receptor was also observed in HEK293 cells 
over-expressing the CB2 receptor.  
Conclusions and Implications: In the vascular endothelium of rat coronary artery, 
anandamide induces relaxation via a mechanism requiring sphingosine kinase-1 and 
S1P/S1P3.  In addition, we report that S1P may exert some of its effects via a CB2 
receptor- and sphingosine kinase-dependent mechanism, where subsequently 
formed S1P may have privileged access to S1P3 to induce vascular relaxation. 
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Abbreviations:  AM251, N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-
4-methyl-1H-pyrazole-3-carboxamide; AM630, 6-Iodo-2-methyl-1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone; Anandamide, 
Arachidonylethanolamide; CA, coronary artery; CAY10444, 2-undecyl-thiazolidine-4-
carboxylic acid; CB, cannabinoid; COX, cyclooygenase; eNOS, endothelial nitric 
oxide synthase; ERK-1/2, extracellular signal-regulated kinase-1/2; GTPγS, 
guanosine 5’- [γ-thio]triphosphate; GPCR, G-protein coupled receptor; HA, 
hemagglutinin; HU210, (6aR)-trans-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-
hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol; JTE-013, 1-[1,3-Dimethyl-4-
(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(3,5-dichloro-4-pyridinyl)-
semicarbazide; JTE907, N-(1,3-Benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-
oxo-8-(pentyloxy)-3-quinolinecarboxamide; pERK-1/2, phospho-extracellular signal-
regulated kinase-1/2; pSK, phospho-sphingosine kinase; SK, sphingosine kinase; 
SKi, 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole; S1P, sphingosine-1-phosphate; 
U46619, 9,11-dideoxy-9α,11-methanoepoxy prostaglandin F2α; VPC23019, (R)-
phosphoric acid mono-[2-amino-2-(3-octyl-phenylcarbamoyl)-ethyl] ester; W146, (R)-
3-Amino-(3-hexylphenylamino)-4-oxobutylphosphonic acid. 
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INTRODUCTION  
The psychotropic effects of cannabinoids are well established.  There is also growing 
evidence for the role of endogenous cannabinoids in the regulation of the 
cardiovascular system, with the release of endogenous cannabinoids in response to 
stress such as during myocardial infarction reported as being cardioprotective, 
reducing tissue damage and arrhythmia (Hajrasouliha et al., 2008).  Cannabinoids 
also appear to have a role in modulating vascular tone and the endogenous 
cannabinoid N-arachidonylethanolamide (Anandamide) has been reported to induce 
relaxation in a variety of vessels, both resistance and conduit, including aorta, 
mesenteric, hepatic and coronary arteries (CAs) (Herradon et al., 2007, Ho and 
Randall, 2007, White et al., 2001, Zygmunt et al., 1999).  However, no clear 
consensus has been reached with regards to the mechanisms governing this 
relaxation.   
 
Cannabinoids can exert their effects via activation of two specific G-protein coupled 
receptors (GPCRs) designated CB1 and CB2, both of which are Gi/o-coupled and act 
to inhibit adenylyl cyclase (Howlett et al., 1986, Felder and Glass, 1998).  Several 
studies have reported the importance of these cannabinoid receptors in mediating 
responses to anandamide, with vascular relaxation mainly attributed to activation of 
the CB1 receptor (Romano and Lograno, 2006, O'Sullivan et al., 2004).  Conversely, 
a body of evidence also exists proposing that the effects of anandamide cannot be 
accredited to either cannabinoid receptor subtype (Grainger and Boachie-Ansah, 
2001, White et al., 2001, Herradon et al., 2007).  The existence of a novel 
endothelial receptor referred to as a ‘non-CB1/nonCB2’ cannabinoid receptor has 
been proposed and this receptor has been reported to play a role in mediating 
relaxation to anandamide (Offertaler et al., 2003, Herradon et al., 2007, Jarai et al., 
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1999).  In addition, anandamide has been shown to act as a ligand for transient 
receptor potential vanilloid type 1 (TRPV1) channels (Smart et al., 2000) and in 
some arteries, such as rat mesenteric the vasodilator effects of anandamide have 
been attributed to its interaction with this receptor, resulting in release of the potent 
vasodilator peptide CGRP from sensory nerve endings (Zygmunt et al., 1999, Ho 
and Hiley, 2003).  Furthermore, the role of the vascular endothelium in the 
vasodilator process is also unclear, as both endothelium-dependent and 
endothelium-independent mechanisms of anandamide-induced relaxation have been 
proposed (White et al., 2001, Pratt et al., 1998, Grainger and Boachie-Ansah, 2001, 
Ho and Hiley, 2003). 
 
At an intracellular level, several mediators have been suggested to facilitate the 
effect of anandamide.  For instance, in bovine ophthalmic arteries and rat aorta, 
generation of nitric oxide mediates relaxation to anandamide (Romano and Lograno, 
2006, Herradon et al., 2007).  Studies in a variety of other vessels have also 
implicated the enzyme cyclooxygenase (COX) in the vasoactive effects of 
anandamide; some proposing that COX metabolises anandamide following its 
cellular uptake resulting in the production of vasodilator eicosanoids (Grainger and 
Boachie-Ansah, 2001, Herradon et al., 2007, Ho and Randall, 2007).  Moreover, 
release of endothelium-derived hyperpolarising factor has also been suggested to 
play a role in anandamide-induced relaxation (O'Sullivan et al., 2004).  In summary, 
the mechanisms mediating this vasodilator response to anandamide appear to vary 
significantly depending on the vascular region and species under investigation. 
 
The bioactive lipid mediator sphingosine-1-phosphate (S1P) is also cardioprotective 
and plays an important role in regulating vascular tone.  Synthesised from 
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sphingosine by the enzyme sphingosine kinase (SK1 and SK2), S1P can exert many 
of its biological effects via five specific GPCRs designated S1P1-5 (Chun et al., 2002, 
Pyne et al., 2009).  In the vasculature S1P1, S1P2 and S1P3 are involved in 
modulating vascular tone, with the degree and type of vascular response varying 
between species and vascular beds (Alewijnse et al., 2004, Hemmings, 2006, Peters 
and Alewijnse, 2007). For example, mesenteric arteries from the rat have been 
reported to constrict in response to S1P, whereas rat aorta will dilate when exposed 
to similar concentrations of S1P (Hemmings et al., 2004, Roviezzo et al., 2006).  The 
effect of S1P on vascular tone appears to depend on the receptor subtypes 
expressed within that vessel and the distribution of these receptors (Coussin et al., 
2002).  S1P1 which is highly expressed on vascular endothelium can mediate 
vasorelaxation via endothelial nitric oxide synthase (eNOS) activation (Igarashi et al., 
2001, Igarashi and Michel, 2000).  Conversely, S1P is able to increase intracellular 
calcium levels and activate Rho kinase in smooth muscle cells via S1P2 leading to 
vasoconstriction (Peters and Alewijnse, 2007, Hemmings, 2006).  Therefore, the 
receptor subtype expression within a vascular bed and the balance between 
vasodilator and vasoconstrictor signals stimulated by S1P will determine its overall 
effect on vascular tone.  
 
S1P and cannabinoid receptors both belong to the lysolipid family of GPCRs and 
exhibit a sequence identity of approximately 20% (Sanchez and Hla, 2004).  
Furthermore, a link may exist between the cannabinoid and sphingolipid pathways 
as cannabinoids have been shown to regulate sphingolipid metabolism, with 
activation of the CB1 receptor resulting in ceramide accumulation in a variety of cell 
types (Blazquez et al., 1999, Galve-Roperh et al., 2000).  In addition to this, 
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sphingosine and its analogue, the immunosuppressant FTY720, have also been 
reported to interact with the CB1 receptor (Paugh et al., 2006). 
Therefore, given the role of both anandamide and S1P in mediating cardioprotection 
and regulating vascular tone, the present study aims to examine the mechanisms 
involved in the anandamide- and S1P-mediated regulation of rat coronary vascular 
tone, and to determine whether any functional interaction/overlapping signalling 
pathways occurs between these systems.   
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MATERIALS AND METHODS 
Materials 
Anandamide (in Tocrisolve™100), AM630, JTE907 and AM251 were purchased 
from Tocris Bioscience (Bristol, UK).  Sphingosine-1-phosphate, VPC23019 and 
W146 were from Avanti Polar Lipid (Alabaster, AL).  4-(4-(4-chlorophenyl)thiazol-2-
ylamino)phenol (SKi), U46619 and G418 were from Merck Biosciences Ltd 
(Nottingham, UK) and CAY10444 was from Axxora (Nottingham, UK). The following 
chemicals were purchased from Sigma-Aldrich (Poole, UK): Indomethacin, 
Acetylcholine, Insulin and Phenylmethanesulphonylfluoride (PMSF).  Cell culture 
supplies were obtained from Invitrogen (Paisley, UK).  Anti-ERK-2 and anti-
phosphorylated ERK-1/2 antibodies were from BD Biosciences (Oxford, UK), anti-
phospho-specific sphingosine kinase 1 (Ser-225) from ECM Biosciences (Versailles, 
KY) and anti-hemagglutinin (HA) antibody from Sigma-Aldrich (Poole, UK).  GTPγS 
and [35S]-GTPγS (1250Ci/mmol) were purchased from Bioquote Ltd (York, UK) and 
Perkin Elmer LAS (Beaconsfield, UK) respectively. 
 
Tissue Preparation and Myography 
All experimental procedures complied with the United Kingdom Animals (Scientific 
Procedures) Act 1986 and the Guide for the Care and Use of Laboratory Animals 
published by the US National Institute of Health (NIH Publication No. 85-23, revised 
1996).  Male Sprague Dawley rats (250-400g body weight) were killed with a rising 
concentration of CO2 and the heart removed and transferred to cold modified Krebs-
Henseleit solution (NaCl 118mM, NaHCO3 25mM, KCl 4.7mM, KH2PO4 1.2mM, 
MgSO4 1mM, CaCl2 2.5mM and glucose 11mM).  The left anterior descending and 
right CAs were then carefully dissected free from the heart tissue.  2mm segments 
were mounted in a wire myograph and maintained at 37oC in Krebs-Henseleit 
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solution with a constant supply of 95%O2/5%CO2.  Vessels were then normalised to 
a tension equivalent to that generated at 90% of the diameter of the vessel at 
100mmHg (Mulvany and Halpern, 1977).  Tissue was allowed to equilibrate for 30 
minutes prior to challenge with 80mM KCl to assess viability.  In order to determine 
vascular endothelial function, vessels were precontracted with the thromboxane A2 
mimetic U46619 (0.3µM) and the response to 1µM acetylcholine (ACh) observed.  
Relaxation to ACh >50% denoted endothelium intact vessels.  Where indicated, 
vessels were denuded of endothelium by gentle rubbing of the intimal surface with a 
human hair.  Successful denudation was confirmed by a vasodilator response to 
ACh of <10%.  
 
Myography Experimental Protocol 
After 30 minutes equilibration, vessels were sub-maximally precontracted with 
U46619 (0.3 µM).  When a stable level of contraction was achieved, concentration-
response curves were generated by cumulative addition of agonist.  Anandamide 
and sphingosine-1-phosphate (S1P) (1nM - 30µM) were added in half-log molar 
concentrations in a cumulative manner with five minutes between each addition.  In 
the case of anandamide, PMSF (200µM) an anandamide breakdown inhibitor was 
added 10 minutes prior to the first addition.  In experiments where the effects of 
inhibitors on agonist-induced relaxation were to be investigated, the inhibitor of 
interest was added 10 minutes before precontraction with U46619 and was present 
during construction of the concentration response curve. 
 
Cell Culture 
Human embryonic kidney 293 (HEK 293) cells were maintained at 37oC with 5% CO2 
in Dulbecco's modified Eagle medium (DMEM) supplemented with essential amino 
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acids, penicillin (50U/ml), streptomycin (50µg/ml) and 10% (v/v) foetal calf serum 
(FCS) whereas stable over-expressing HA-tagged CB2 receptor HEK 293 (CB2 HEK 
293) cells (gift from Prof K Mackie, Indiana University, IN, USA) were maintained in 
DMEM supplemented with 10% (v/v) FCS and 800µg/ml G418, also known as 
Geneticin).  All HEK 293 cells were quiesced in serum free medium for 24 hours 
before experimentation.  MCF-7 cells were grown in DMEM supplemented with 
penicillin (50U/ml), streptomycin (50µg/ml), 10% (v/v) FCS, 0.4% G418 and 15µg/ml 
insulin and maintained at 37oC with 5% CO2.  MCF-7 cells were quiesced for 48 
hours in serum free media before experimentation. 
 
[35S]GTPγS (guanosine 5’- [γ-[35S]thio]triphosphate) Binding Assay 
HEK293 or CB2 HEK293 cells were homogenized in buffer containing 20mM HEPES 
(pH7.5), 50mM NaCl and 2mM EDTA.  Nuclei and cell debris were removed by 
centrifugation at 2000G for 5 minutes at 4oC and the resulting supernatant 
centrifuged at 100000G for 1 hour at 4oC.  The pellet containing the membrane 
fraction was then rinsed with and resuspended in buffer containing 50mM HEPES 
(pH7.5), 100mM NaCl, 1mM MgCl2 and 2mM EDTA.  Samples containing 20µg of 
membrane protein were then incubated for 15 minutes at 30oC in buffer containing 
50mM HEPES (pH7.5), 100mM NaCl, 5mM MgCl2, 10µM GDP, 2mM DTT, 0.1nM 
[35S]GTPγS and the indicated concentrations of agonist and/or antagonist.  Non 
specific binding was determined in the presence of unlabelled GTPγS (20µM).  
Reactions were terminated by rapid filtration through GF/C glass fibre filters using a 
24-well Brandel Cell Harvester.  Filters were then rinsed with wash buffer containing 
20mM Tris/HCl (pH7.4), 120mM NaCl and 25mM MgCl2 and membrane bound 
radioactivity quantified by liquid-scintillation counting.  Samples were run in 
duplicate.   
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 Immunoblotting 
In experiments where rat coronary artery tissue was used, vessel rings were 
mounted in a wire myograph and the tension on the vessels normalised as already 
described prior to stimulation with anandamide for 30 minutes. Vessel rings were 
then carefully removed from the myograph.  Four coronary artery rings were pooled 
together and homogenised in RIPA buffer (50mM sodium HEPES, pH 7.5, 150mM 
sodium chloride, 5mM EDTA, 10mM sodium fluoride, 10mM sodium phosphate, 1% 
(v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 0.1mM 
phenylmethylsulphonyl fluoride, 10µg/ml soybean trypsin inhibitor, 10µg/ml 
benzamidine) to make one sample.  Analysis of proteins by SDS-PAGE and 
immunoblotting was performed as previously described (Long et al., 2006) using 
anti-ERK2, anti-phosphorylated ERK1/2, anti-HA and anti-phospho-SK1 antibodies.  
Densitometry was performed on each resulting film exposure to determine 
normalised levels of the protein of interest using Molecular Analyst software version 
2.1. 
 
Statistical Analysis 
Relaxation responses are expressed as a percentage loss of the tone induced by 
U46619.  EC50 values were obtained from individual concentration-response curves 
by fitting the data to a logistics equation (GraphPad PRISM version 4).  Data are 
given as mean ± SEM of n, where n = the number of arteries from different animals.  
Statistical comparisons of concentration-response curves were made by two-way 
ANOVA of the whole data set.  Where appropriate one-way ANOVA with Newman-
Keuls multiple comparison post tests were employed.  P values less than 0.05 were 
considered to be statistically significant. 
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All drug/molecular target nomenclature conform to the British Journal of 
Pharmacology Guid to Receptors and Channels (Alexander et al.,2009)  
RESULTS 
Anandamide induces vascular relaxation via the cannabinoid 2 (CB2) receptor 
subtype. 
Addition of anandamide (1nM-30µM) to U46619-pre-contracted intact rat CA resulted 
in a concentration-dependent, slowly developing relaxation, which reached a 
maximum of 42.1±5.9%, EC50 2.36x10-8M, n=13.  The relaxant effect of anandamide 
was not reduced by denudation of the endothelium (maximal relaxation 44.6±4.1%, 
EC50 2.23x10-8, n=7, Figure1A). 
 
The pre-treatment of the vessels with the selective CB1 receptor antagonist AM251 
(10µM) did not significantly alter the magnitude of the vasorelaxation induced by 
anandamide (n=6, Figure 1B, Table 1).  However, the CB2 selective antagonist 
AM630 (100nM) significantly attenuated the relaxant response to anandamide (n=4, 
p<0.05, Figure1C),.  Initial experiments using AM630 at a higher concentration of 
10µM also attenuated anadamide-mediated relaxation reducing the maximal 
relaxation to 28.5±5.8%, n=6, p<0.05, Table1).  Similarly, the CB2 selective inverse 
agonist JTE907 (10µM) also markedly reduced relaxation in response to 
anandamide (maximal relaxation 12.8±2.5%, n=5, Table 1).  However, in 
endothelium denuded vessels AM630 (100nM) had no effect on the ability of 
anandamide to induce vascular relaxation (n=4, Figure 1D, Table 1). 
 
In addition to the vasodilator effects of anandamide, HU210 a non-selective CB1/2 
agonist also mediates relaxation of the rat CA.  This response was not inhibited by 
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the CB1 antagonist AM251 (n=5, Figure 1E, Table 1).  It was however significantly 
attenuated by the CB2 antagonist AM630 (10µM) (n=4, p<0.05, Figure 1F, Table 1). 
 
S1P stimulates vascular relaxation in an endothelium-dependent manner. 
To confirm that S1P is a vasorelaxant in rat CA, its effect on CA tone was directly 
assessed.  In endothelium-intact U46619 pre-contracted arteries, S1P caused a 
concentration-dependent relaxation.  In common with anandamide, this was a slow 
onset response resulting in a maximum relaxation of 47.7±7.3%, n=10 (Figure 2A, 
Table 2).  In vessels where the endothelial layer was removed, relaxation in 
response to S1P was markedly reduced (maximal relaxation 22.5±10%, n=8, p<0.05, 
Figure 2A, Table 2).  Furthermore, responses to S1P were not significantly inhibited 
by the S1P1 antagonist W146 (Figure 2B, Table 2, n=5) or JTE013, an S1P2 
antagonist (Figure 2C, Table 2, n=6).  However, the S1P3 antagonist CAY10444 did 
significantly attenuate S1P-mediated relaxation (22±6.2%, n=5, p<0.05, Figure 2D, 
Table 2). 
 
Role for cyclooxygenase (COX) in anandamide and S1P-mediated relaxation.  
The non-selective COX inhibitor indomethacin (10µM) was utilised to determine 
whether COX plays a role downstream of anandamide and S1P in mediating 
vascular relaxation in the rat CA.  Pre-incubation with indomethacin significantly 
reduced the vasodilator effect of anandamide in endothelium-intact vessels (maximal 
relaxation 22.7±4.7%, n=7, p<0.05, Figure 3A, Table 1) but did not significantly alter 
responses to anandamide in denuded vessels (maximal relaxation 56.5±9.1%, n=4, 
Figure 3B, Table 1).  Responses to S1P in intact vessels were also significantly 
attenuated in the presence of indomethacin (maximal relaxation 11±15.8%, n=4, 
 13
p<0.05, Figure 3C, Table 2), indicating the involvement of COX in both anandamide- 
and S1P-induced relaxation of rat CA.   
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Sphingosine kinase is required for anandamide-induced relaxation. 
Stimulation of rat coronary artery rings with anandamide resulted in a 50.9±11.8% 
increase in the Ser225 phosphorylation of SK1 (n=4, p<0.05, Figure 4A).  The 
phosphorylation of SK1 on Ser225 has been demonstrated before in response to 
agonist stimulation, and is catalysed by ERK-1/2 (Pitson et al., 2003).  Indeed,  
anandamide stimulation of rat coronary artery rings also increased in the levels of 
phosphorylated ERK-1/2 (33.1±6.4% increase, n=4, p<0.05, Figure 4A).  The SK1 
inhibitor, SKi, 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole (French et al., 2003) 
also had a marked effect on responses to anandamide, almost completely inhibiting 
relaxation (maximal response 2.3±6.2%, n=5, p<0.05, Figure 4B, Table 1), 
suggesting that anandamide-mediated vasorelaxation requires SK1/S1P.  In contrast 
to this, incubation with SKi has no effect on anandamide-mediated relaxation in 
endothelium-denuded vessels (n=4, Figure 4C, Table 1), highlighting a role for 
SK1/S1P specifically within the vascular endothelium   
 
Anandamide-induced relaxation is mediated by S1P3 within the vascular 
endothelium.  
Selective S1P antagonists were utilised to determine if the S1P that would be 
potentially formed by the anandamide-mediated phosphorylation and activation of 
SK1 can mediate its effects by acting via S1P receptors.  The selective S1P1/3 
antagonist, VPC23019, significantly attenuated anandamide-mediated relaxation in 
the rat coronary artery (maximal response 16.8±2.5%, n=8, p<0.05, Figure 5A, Table 
1) but had no effect on the anandamide response in denuded arteries, suggesting 
any S1P produced in response to anandamide exerts its effect by acting on S1P1/3 
receptors on the vascular endothelium (maximal relaxation 39.6±3.3 %, n=8, Figure 
5B, Table 1).  To determine the individual effects of S1P1 and S1P3 in mediating the 
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anandamide response selective S1P1 and S1P3 were employed.  W146, a selective 
S1P1 antagonist had no effect on anandamide-induced relaxation (Figure 5C, Table 
1).  Similar to its effects on exogenously added S1P, the S1P3 antagonist CAY10444 
was found to significantly reduce the relaxation to anandamide in endothelium-intact 
vessels (maximal relaxation 15.9±2.9%, n=5, Figure 5D, Table 1).  However, in 
endothelium-denuded vessels the inhibitory effect of CAY10444 was no longer 
observed (maximal relaxation 52±6.1 %, n=6, Figure 5E, Table 1), indicating that 
anandamide-induced relaxation involves the activation of S1P3 on the vascular 
endothelium.  Furthermore, combined pretreatment with both AM630 (100nM) and 
CAY10444 (10µM) while inhibiting the anandamide response does not have an 
additive effect in attenuating vascular relaxation, suggesting that anandamide does 
not act directly on S1P3.  
 
S1P induced relaxation involves CB2 receptors and requires SK to mediate its 
effect. 
To further investigate the relationship between S1P and anandamide mediated 
responses, we examined whether S1P responses involved cannabinoid receptors.  
The pre-treatment of the rat CA with the CB2 antagonist AM630 significantly 
attenuated S1P-mediated relaxation, reducing the maximal relaxation to 25±7.3%, 
n=6, p<0.05 (Figure 6A).  The CB2 inverse agonist JTE907 also markedly reduced 
relaxation in response to S1P (maximum relaxation 21.2±3.8%, n=5, p<0.05, Figure 
6B).  Furthermore, in MCF-7 cells where ERK-1/2 activation responses to S1P are 
S1P3-mediated (Sukocheva et al., 2006), and can be completely abolished by pre-
treatment with CAY10444, neither AM630 nor JTE907 had any effect on the ability of 
S1P to activate ERK-1/2 (n=4, Figure 6C), demonstrating that neither AM630 nor 
JTE907 are S1P3 antagonists. Therefore, we can rule out the possibility that these 
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antagonists block S1P3 receptors in the vessels.  In addition, similar to anandamide, 
relaxant responses to S1P were significantly decreased in the rat CA in the presence 
of the SK1 inhibitor, SKi (22.8±7.7%, n=5, p<0.05, Figure 6D), suggesting that S1P-
induced vasorelaxation requires SK1. 
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S1P functionally interacts with CB2 receptor activation. 
The findings presented in Figure 5 suggest that S1P may activate CB2 receptors in 
the rat coronary artery.  In order to further establish whether S1P can functionally 
interact with CB2 receptors, cell based assays using HEK293 cells which stably over-
express CB2 receptors (CB2HEK293s) were carried out.  Experiments were also 
undertaken using parental HEK293s for comparison; these cells also endogenously 
express S1P receptors (see later for effect of S1P and CB2 receptor antagonists).  
Firstly, [35S]GTPγS binding assays were undertaken in these cells to establish if S1P 
can activate CB2 receptors.  HU210, a known CB1/2 receptor agonist was found to 
stimulate [35S]GTPγS binding in CB2HEK293 cells but not parental HEK 293s (n=3, 
p<0.05, Figure 7A).  Similarly, treatment with S1P also resulted in an increase 
[35S]GTPγS binding in CB2HEK293s but not parental cells (n=3, p<0.05, Figure 7B).  
Furthermore, the elevation in [35S]GTPγS binding to CB2HEK293 membranes 
stimulated by both HU210 and S1P was significantly attenuated by the CB2 
antagonist AM630 (n=4, p<0.05, Figure 7C), suggesting both HU210 and S1P are 
agonists of the CB2 receptor. 
 
The effects of S1P and antagonists on the activation of the ERK-1/2 pathway in 
parental and CB2HEK293 cells was also assessed as a reporter of CB2 receptor 
function. Stimulation of both parental HEK293 and CB2HEK293s cells with S1P 
resulted in a marked elevation in the levels of phoshorylated ERK-1/2 (Figure 8A, 
p<0.01, n=3).  The pre-treatment with either of the CB2 antagonists, AM630 or 
JTE907 alone had no effect on the ability of S1P to induce ERK-1/2 phosphorylation 
in either cell type (Figure 8A).  However, the S1P response was completely 
abolished following pre-treatment of HEK293 cells with a combination of CAY10444 
(20µM) and W146 (20µM), suggesting that in the parental HEK293 cells, S1P 
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induces activation of ERK-1/2 via S1P1/3 (Figure 8B).  In contrast to this, pre-
treatment of CB2HEK293 cells with combined CAY10444 (20µM) and W146 (20µM) 
had no effect on the ability of S1P to induce ERK-1/2 activation (Figures 8B), 
suggesting that the major effect of S1P in these cells is mediated via a distinct 
receptor.  Evidence that this distinct receptor might be CB2, was obtained by results 
showing that the stimulatory effect of S1P on ERK-1/2 activation was no longer 
observed in CB2 HEK293 cells that were treated with AM630 in addition to 
CAY10444 and W146 (Figure 7B).  Similar results were also obtained using JTE907 
in the presence of S1P antagonists (data not shown).  The pre-treatment with 
combined W146 and CAY10444 and AM630 or JTE907 did not significantly alter 
basal levels of phosphorylated ERK in either cell type. 
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DISCUSSION 
Anandamide and S1P both play an important role in regulating vascular tone.  Here 
we show that both these lipid mediators stimulate relaxation in isolated rat CAs and 
that a functional interaction between these receptor systems exists within the 
vascular endothelium to regulate vasorelaxation. 
 
Various studies have reported the role of the CB1 receptor in mediating relaxation to 
anandamide (Romano and Lograno, 2006, O'Sullivan et al., 2004).  However, the 
present study found that AM251, a selective CB1 antagonist had no effect on 
anandamide-induced vasorelaxation.  Blocking CB2 receptors, on the other hand, 
with either AM630 or JTE907, significantly attenuated the effects of anandamide.  
Similar effects were also observed on relaxation to the synthetic cannabinoid agonist 
HU210 (.  These findings suggest the CB2 receptor is important in mediating the 
effects of cannabinoid agonists on rat CA reactivity.  Moreover, the inhibitory effect of 
AM630 on anandamide-mediated relaxation is abolished in endothelium-denuded 
vessels, specifically implicating the vascular endothelium in CB2 receptor-mediated 
vascular relaxation.  The CB2 receptor has mainly been suggested to play a role in 
cardioprotection.  For instance, remote ischaemic preconditioning is thought to 
involve the release of endogenous cannabinoids, which exert their cardioprotective 
effect by acting on the CB2 receptor (Hajrasouliha et al., 2008).   
 
Similar to anandamide, we found that S1P also induced relaxation of the rat CA and 
that this effect was significantly attenuated by removal of the vascular endothelium.  
Furthermore, this vasodilator effect of S1P appears to be mediated by activation of 
S1P3, as CAY10444 was able to significantly attenuate S1P-induced vascular 
relaxation.  A large body of evidence exists implicating S1P3 in the vasodilator 
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effects of S1P, mainly via activation of eNOS (Nofer et al., 2004).  However, in this 
instance, pre-treatment of the coronary vessels with L-NAME had no effect on S1P-
stimulated relaxation suggesting NO is not involved in the vasoactive effects of S1P 
in this vessel (data not shown). 
 
Both anandamide and S1P induce relaxation of a similar magnitude in the rat CA, 
which is partially sensitive to the COX inhibitor indomethacin, suggesting a common 
downstream pathway involving a vasodilator prostanoid.  Only the endothelium-
dependent component of anandamide-induced relaxation is inhibited by 
indomethacin.  Furthermore, the effects of S1P are also dependent on the 
endothelial layer, suggesting any common pathway shared by anandamide and S1P 
may occur specifically within the vascular endothelium. 
 
Recently cannabinoids have been implicated in the regulation of sphingolipid 
metabolism (Giuliano et al., 2006).  In this study we investigated the potential role of 
SK1, the enzyme responsible for synthesising S1P, in mediating the effects of 
anandamide.  There are two mammalian SK isoforms, SK1 and SK2, which are 
ubiquitously expressed.  SK1 can be phosphorylated by ERK-1/2 (Pitson et al., 
2003), which results in the phosphorylation of the enzyme on Ser225.  This 
phosphorylation is required for translocation of SK1 to the plasma-membrane, where 
it produces S1P for ‘inside-out’ signaling at S1P receptors.  This involves the release 
of S1P into the extracellular milieu and/or partition into lipid micro-environments in 
close proximity to the S1P receptor, therefore allowing privileged and efficient 
binding of S1P to the S1P receptor.  Indeed, various stimuli shown to activate SK1, 
induce its translocation to the plasma membrane (Sarkar et al., 2005, Melendez and 
Khaw, 2002).Here we demonstrate that stimulation of the rat CA with anandamide 
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stimulates Ser225 phosphorylation of SK1, suggesting a potential role for SK1 in 
‘inside-out’ signalling.  The pre-treatment of rat CAs with the SK inhibitor SKi also 
completely abolished the ability of anandamide to induce relaxation, thereby 
suggesting a role for SK1 in mediating the effects of anandamide.  SKi also had 
similar effects on HU210-induced relaxation (data not shown).  Additionally, the 
inhibitory effect of SKi on anandamide-mediated relaxation was dependent on the 
vascular endothelium.  Moreover, CAY10444, an S1P3 antagonist, significantly 
attenuated anandamide-induced relaxation.  This effect was also abolished by 
removal of the vascular endothelium.  These findings suggest that SK1 is required 
downstream of cannabinoids and that S1P that is likely to be formed then acts at 
S1P3 to induce vasorelaxation, a process that appears to occur specifically within the 
endothelial layer. To support this model others have demonstrated that the 
generation of intracellular S1P by the activation of SK1 is involved in mediating the 
effects of various agonists and phorbol esters (Taha et al., 2006, Alemany et al., 
2007).  Furthermore, S1P can be released from cells to exert its effects 
extracellularly via S1P receptors (Kobayashi et al., 2006).  Endothelial cells have 
been reported to release both S1P and active SK to form S1P outside the cell 
(Ancellin et al., 2002, Venkataraman et al., 2006).  Finally, in cardiac myocytes a 
similar mechanism of action has been proposed for the adipose-derived plasma 
protein adiponectin (APN) whereby APN was found to activate SK to generate S1P 
which then exerted its effects via activation of the S1P1/3 (Ikeda et al., 2008).   
 
The role of the CB2, S1P/SK1 and S1P3 in anandamide-induced relaxation appears 
confined to the endothelial layer.  However, in denuded vessels anandamide still 
induces relaxation to a magnitude similar to that observed in endothelium intact 
vessels.  This suggests that a compensatory mechanism exists within the vascular 
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smooth muscle allowing anandamide to mediate vasorelaxation in the event of 
endothelial damage.  Others have also reported the existence of distinct 
mechanisms that regulate the effects of anandamide in vascular endothelium and 
smooth muscle (O'Sullivan et al., 2004, Romano and Lograno, 2006, Mukhopadhyay 
et al., 2002).  Although not investigated in the current study in rat CA, one potential 
compensatory mechanism that may mediate anandamide-induced relaxation in the 
absence of the vascular endothelium is the activation of large conductance Ca2+-
activated K+ channels (BKca).  BKca have previously been reported to be activated by 
anandamide  within vascular smooth muscle, inducing relaxation (White et al.,2001).    
 
We conclude from the current findings that two distinct mechanisms of anandamide-
induced relaxation exist, one dependent on the vascular endothelium involving the 
CB2 receptor, S1P/S1P3 and COX, in addition to another compensatory mechanism 
that acts independently of the endothelial layer. 
 
In addition to this, S1P may elicit its effects via a process that requires the CB2 
receptor, as both AM630 and JTE907 significantly reduced the vasorelaxant 
response to S1P in the rat CA.  The effect is not due to the blockade of S1P3 as 
neither AM630 nor JTE907 attenuated the ability of S1P to induce ERK-1/2 
activation in MCF-7 cells, a breast cancer cell line where the effects of S1P are via 
S1P3 activation (Sukocheva et al.,2006).  Moreover, AM630 and JTE907 did not 
modify the activation of ERK-1/2 by S1P in parental HEK293s, which express 
functional S1P1 and S1P3.  The finding that S1P induced relaxation is blocked by 
CB2 receptor antagonists suggests that S1P might use the CB2 receptor in order to 
induce vascular relaxation.  This is supported by our studies using CB2 HEK293 cells 
where S1P was shown to stimulate GTPγS binding, and that this was blocked by 
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AM630.  Furthermore, ERK-1/2 activation in response to S1P in these cells was still 
observed following pre-treatment with a combination of S1P1 and S1P3 antagonists 
sufficient to significantly reduce S1P-induced ERK-1/2 activation in the parental 
HEK293 cells.  In addition, the ability of S1P to stimulate ERK activation in CB2 
HEK293s when S1P1/3 are blocked is completely ablated when these cell are 
concurrently treated with CB2 antagonists.  Given that CB2 antagonists on their own 
have no inhibitory effect of S1P-mediated ERK activation unless S1P1/3 are blocked, 
these findings suggest that S1P may activate CB2 receptors in HEK293 cells to 
initiate downstream signalling cascades when the functionality of S1P receptors is 
experimentally impaired.  Others have also highlighted a link between lysolipids and 
cannabinoid receptors.  For instance, sphingosine has been shown to interact with 
cannabinoid receptors; this study reported that sphingosine and its analogue 
FTY720 were able to bind to CB1 receptors where they acted as antagonists (Paugh 
et al., 2006).  Moreover, both cannabinoids and lysophosphatidylinositol (LPI), an 
acidic lysophospholipid similar to S1P, have been proposed to act as agonists at the 
orphan GPCR, GRP55 (Oka et al., 2007).   
 
We also observed that relaxation to S1P in the rat CA is significantly reduced by SKi, 
suggesting a role for SK1 downstream of CB2 receptors.  Thus, in rat CA, stimulation 
of CB2 receptors in response to S1P may provide an alternative mechanism by which 
S1P mediates vascular relaxation through the generation of intracellular S1P, which 
is then released locally to access S1P3.  This mechanism may deliver S1P more 
efficiently to S1P3 compared with exogenous S1P, suggesting privileged access to 
S1P receptors, possibly via efficient disposition of S1P in a lipid microdomain in 
close proximity to S1P3.   
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In summary, both anandamide and S1P induced vascular relaxation in the rat CA, 
with the involvement of both CB2 and S1P3.  Within the vascular endothelium both 
lipid mediators require COX to exert their vasodilator effects, potentially by 
prostaglandin production. Phosphorylation of ERK-1/2 is known to activate cytosolic 
phospholipase A2 resulting in an increase in arachidonate production and 
subsequent prostanoid production via COX.  Therefore, ERK activation within the 
coronary artery in response to anandamide may result in the production of 
vasodilator prostaglandins.   For the first time we demonstrate that SK1 has an 
important role in anandamide-induced relaxation and suggest that activation of SK1 
by anandamide may result in the generation of S1P which can then exert its effects 
via activation of S1P3 on the vascular endothelium.  We also provide evidence that 
S1P might use the CB2 receptor to stimulate localised production of S1P in the 
vicinity of S1P3, the activation of which mediates coronary vascular relaxation. 
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Figure 1.  Anandamide induces vascular relaxation via the CB2 receptor.    
Concentration-response curves for the vasorelaxant effect of anandamide (1nM-
30µM) in A endothelium-intact (n=13) and endothelium-denuded (n=7) rat CA and 
concentration-response curves for the relaxation of U46619-induced tone in 
endothelium-intact rat CA for anandamide (1nM-30µM) in the presence of B AM251, 
a selective CB1 antagonist (10µM) (n=6), C AM630, a selective CB2 antagonist 
(100nM) (n=5) and D AM630 (100nM), (n=4) in endothelium-denuded rat CA.  D 
concentration-response curves showing the vasorelaxant effect of HU210 alone 
(1nM-30µM) and in the presence of AM251 (10µM) (n=6) and E in the presence of 
AM630 (10µM) (n=4).  Data are expressed as a percentage of U46619-induced tone 
and shown as mean ± SEM for n arteries from different animals..  * P<0.05 versus 
anandamide alone as determined by two-way ANOVA. 
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Figure 2.  S1P stimulates vascular relaxation in an endothelium-dependent manner.  
A Concentration-response curves showing the vasorelaxant effect of S1P (1nM-
30µM) on U46619-precontracted endothelium-intact (n=10) and endothelium-
denuded (n=8) isolated rat CA and concentration-response curves showing the effect 
of S1P (1nM-30µM, n=10) in the presence of B W146, a selective S1P1 antagonist 
(10µM) (n=5), C JTE013, a selective S1P2 antagonist (10µM) (n=6) and D 
CAY10444, a selective S1P3 antagonist (10µM) (n=5) in endothelium-intact U46619-
precontracted rat CA.  Data are expressed as a % of U46619-induced tone and 
shown as mean ± SEM for n arteries from different animals .  * P<0.05 versus S1P 
alone as determined by two-way ANOVA. 
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Figure 3.  Role for COX in anandamide and S1P-mediated relaxation.  
Concentration-response curves for the vasorelaxant effect of anandamide alone 
(1nM-30µM, n=13) and in the presence of indomethacin 10µM in A endothelium-
intact (n=7) and in B endothelium-denuded (n=6) U46619-precontracted rat CA.  C 
concentration-response curves showing the vasorelaxant effect of S1P alone (1nM-
30µM, n=10) and in the presence of indomethacin 10µM (n=4) in endothelium-intact 
U46619-precontracted rat CA.  Data are expressed as a percentage of U46619-
induced tone and shown as mean ± SEM for n arteries from different animals .  * 
P<0.05 versus anandamide or S1P alone as determined by two-way ANOVA.   
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Figure 4.  Sphingosine kinase is required for anandamide-induced relaxationin the 
rat coronary artery.  A Representative immunoblot showing the effect of anandamide 
(10µM) on pSK1, pERK-1/2 and ERK2 levels in rat coronary artery rings.  Graphs 
shows quantitation of densitometry results expressed as mean ± SEM for 4 separate 
samples.. * P<0.05 versus vehicle as determined by students unpaired two-tailed t-
test.   B  Concentration-response curves for the relaxation to anandamide alone 
(1nM - 30µM, n=13) and in the presence of SKi, a selective SK1 inhibitor 10µM (n=5) 
in U46619 precontracted endothelium-intact rat CA and C endothelium denuded rat 
CA (n=4).  Data are expressed as a % of U46619-induced tone and shown as mean 
± SEM for n arteries from different animals .  * P<0.05 versus anandamide alone as 
determined by two-way ANOVA. 
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Figure 5. Anandamide-induced relaxation is mediated by S1P3 within the 
vascular endothelium.  Concentration-response curves for the relaxation to 
anandamide alone (1nM - 30µM, n=13) and in the presence of VPC23019, a S1P1/3 
antagonist (10µM) in A endothelium-intact (n=8) and B endothelium-denuded (n=8) 
U46619 precontracted rat CA. Concentration-response curves for the relaxation to 
anandamide alone (1nM - 30µM, n=13) and in the presence of C W146, a selective 
S1P1 receptor antagonist (10µM) (n=5) and D CAY10444, a selective S1P3 
antagonist (10µM) (n=5)  in U46619 precontracted endothelium-intact rat CA and E 
in the presence of CAY10444 10µM in endothelium-denuded U46619 precontracted 
arteries (n=6).  F Concentration response curves for anandamide alone (n=6) and in 
the presence of a combination of AM630 (100nM) and CAY10444 (10µM) (n=4) in 
endothelium-intact rat CA.  Data are expressed as a % of U46619-induced tone and 
shown as mean ± SEM for n arteries from different animals .  * P<0.05 versus 
anandamide alone as determined by two-way ANOVA. 
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Figure 6.  S1P-induces relaxation via the CB2 receptor and requires SK to mediate 
its effect.  Concentration-response curves showing the vasorelaxant effect of S1P 
alone (1nM-30µM, n=10) and in the presence of A AM630, a selective CB2 receptor 
antagonist (10µM) (n=6) and B JTE907, a selective CB2 receptor antagonist (10µM) 
(n=5) in endothelium-intact U46619-precontracted rat CA.  C representative 
immunoblots showing the effect of CAY10444 10µM (a selective S1P3 antagonist), 
AM630 10µM and JTE907 10µM (both selective CB2 receptor antagonists) on S1P-
mediated (1µM) ERK-1/2 phosphorylation in MCF-7 cells.  Graph shows quantitation 
of densitometry results expressed as mean ± SEM for 4 separate experiments.  D 
concentration-response curves showing the effect of S1P alone (1nM-30µM, n=10) 
and in the presence of Ski, a selective SK1 inhibitor (10µM) (n=5) in endothelium-
intact U46619-precontracted rat CA.  Myography data are expressed as a 
percentage of U46619-induced tone and shown as mean ± SEM for n arteries from 
different animals.  * p<0.05 versus S1P alone as determined by two-way ANOVA.  ** 
p<0.01 versus unstimulated cells and # p<0.05 versus S1P stimulated cells as 
determined by one-way ANOVA with Newman-Keuls post test.   
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Figure 7.  S1P stimulates CB2 receptor activation. 
The effects of A HU210, a CB1/2 agonist (1pM-10nM) (n=3) and B S1P (1nM - 10µM) 
(n=3) on [35S]-GTPγS binding to HEK293 and CB2HEK293 cell membranes. Data 
expressed as a % of maximal HU210-induced [35S]-GTPγS binding.  Results shown 
as mean ± SEM for 3 separate experiments.  * p<0.05 versus HEK293 membranes 
as determined by two-way ANOVA.   C the effects of AM630, a selective CB2 
receptor antagonist (10µM) on HU210 (10µM) and S1P (10µM) mediated [35S]-
GTPγS binding to CB2HEK293 cell membranes.  Data expressed as a % of maximal 
HU210-induced [35S]-GTPγS binding.  Results shown as mean ± SEM for 4 separate 
experiments. ***p<0.001 versus vehicle, ** p<0.01 versus vehicle, # p<0.05 versus 
HU210 and * p<0.05 versus S1P as determined by one-way ANOVA with Newman-
Keuls post test. 
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Figure 8.  S1P stimulated ERK-1/2 activation involves CB2 receptor.  A 
representative immunoblots showing the effect of AM630 (10µM) and JTE907 
(10µM) (both selective CB2 receptor antagonists) and B representative immunoblots 
showing the effect of combined pretreatment with W146, a selective S1P1 antagonist 
(20 µM), CAY10444 (CAY), a selective S1P3 antagonist (20µM) and AM630 (10µM) 
on S1P-mediated (5µM) ERK1/2 activation in lysates prepared from parental 
HEK293 cells and CB2 HEK293s.  Graph shows quantitation of densitometry data 
with results expressed as mean ± SEM for 3 separate experiments.  * p<0.05 and ** 
p<0.01 versus unstimulated cells.  # p<0.05 versus S1P stimulated cells as 
determined by one-way ANOVA with Newman-Keuls post test. 
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Table 1.  Effects of anatagonist and enzyme inhibitors on anandamide and HU210-
mediated relaxation in rat CA.   Data are expressed as mean ± SEM for n arteries 
from different animals.  * p<0.05 versus anandamide alone, # p<0.05 versus HU210 
alone as determined by two-way ANOVA. 
 40
Table 2.  Effects of anatagonist and enzyme inhibitors on S1P-mediated relaxation in 
rat CA.  Data are expressed as mean ± SEM for n arteries from different animals.  * 
p<0.05 versus S1P alone as determined by two-way ANOVA. 
 
 
 41
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60 Anandamide
Anandamide denuded
log[Anandamide](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
A B
C D
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60 Anandamide
Anandamide + AM251
log[Anandamide](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60 Anandamide
Anandamide + JTE907
log[Anandamide](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60 Anandamide
Anandamide + AM630
log[Anandamide](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
*
*
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60 S1P
S1P+W146
log[S1P](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60 S1P
S1P+CAY10444
log[S1P](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
A B
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60 S1P
S1P denuded
log[S1P](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
*
*
-10 -9 -8 -7 -6 -5
0
20
40
60
80 S1P
S1P + JTE013
log [S1P] (M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
C D
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60 Anandamide
Anandamide + Indomethacin
log[Anandamide](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60
70 Anandamide
Anandamide +
Indomethacin
log[Anandamide](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
-9 -8 -7 -6 -5
-10
0
10
20
30
40
50
60 S1P
S1P + Indomethacin
log[S1P](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
A B
C
*
*
A B
C
-9 -8 -7 -6 -5
-10
0
10
20
30
40
50
60 Anandamide
Anandamide + SKi
log[Anandamide](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
*
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60 Anandamide
Anandamide + CAY10444
log[Anandamide](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
*
-9 -8 -7 -6 -5-10
0
10
20
30
40
50
60 Anandamide
Anandamide + CAY10444
log[Anandamide](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
D
pERK 1/2
pSK1
ERK-2
ANANDAMIDE - +
pSK1
Vehicle Anandamide
0.0
0.2
0.4
0.6
0.8
1.0
1.2 *
O
D
*
m
m
*
m
m
pERK
Vehicle Anandamide
0.0
0.5
1.0
1.5
2.0
2.5
*
O
D
*
m
m
*
m
m
C-9 -8 -7 -6 -5-10
0
10
20
30
40
50
60 S1P
S1P+JTE907
log[S1P](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
*
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60 S 1P
S 1P  +  S K i
lo g [S 1P ](M )
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
*
-10 -9 -8 -7 -6 -5
0
10
20
30
40
50
60 S1P
S1P + AM630
log[S1P](M)
R
e
l
a
x
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
U
4
6
6
1
9
-
i
n
d
u
c
e
d
 
t
o
n
e
)
B
D
A JTE907
AM630
CAY10444
S1P
-
-
-
-
-
-
-
+
-
-
+
-
-
-
+
+
-
+
-
-
-
+
-
+
+
-
-
-
+
-
-
+*
pERK 1/2
ERK 2
**
#
** **
JTE907
AM630
CAY10444
S1P
-
-
-
-
-
-
-
+
-
-
+
-
-
-
+
+
-
+
-
-
-
+
-
+
+
-
-
-
+
-
-
+
0
2
4
6
p
E
R
K
 
1
/
2
 
/
 
E
R
K
 
2
r
a
t
i
o
AC
B
-12 -11 -10 -9 -8
-20
0
20
40
60
80
100
120 HEK293
CB2HEK293
log[HU210](M)
%
 
o
f
 
m
a
x
i
m
a
l
 
H
U
2
1
0
-
i
n
d
u
c
e
d
b
i
n
d
i
n
g
-9 -8 -7 -6 -5
-20
0
20
40
60
80
100
120 HEK293
CB2HEK293
log[S1P](M)
%
 
o
f
 
m
a
x
i
m
a
l
 
H
U
2
1
0
-
i
n
d
u
c
e
d
b
i
n
d
i
n
g **
0
25
50
75
100
- +            + - -
- -   vv-             + +
- - +             - +
HU210
S1P
AM630
***
#
**
*
%
 
o
f
 
m
a
x
i
m
a
l
 
H
U
2
1
0
-
i
n
d
u
c
e
d
b
i
n
d
i
n
g
A B
S1P
AM630
JTE907
S1P
CAY/ W146
AM630
0
1
2
3
4
p
E
R
K
 
1
/
2
 
/
 
E
R
K
 
2
 
r
a
t
i
o
**
HEK293s CB2 HEK293s
-
-
-
+
-
-
-
+
-
-
-
+
+
-
+
+
+
-
HEK293s CB2 HEK293s
-
-
-
+
-
-
-
+
-
-
-
+
+
-
+
+
+
-
**
** **
** **
-
-
-
+
-
-
-
+
-
-
-
+
+
-
+
+
+
-
-
-
-
+
-
-
-
+
-
-
-
+
+
-
+
+
+
-
S1P
AM630
JTE907
HEK293s CB2 HEK293s
0.0
0.5
1.0
1.5
2.0
2.5
p
E
R
K
 
1
/
2
 
/
 
E
R
K
 
2
 
r
a
t
i
o
+
-
-
-
-
-
-
+
-
-
+
+
+
+
+
+
+
-
**
*
*
#
#
#
+
-
-
-
-
-
-
+
-
-
+
+
+
+
+
+
+
-
S1P
CAY/ W146
AM630
pERK 1/2
ERK 2 ERK 2
-
-
-
+
-
-
-
+
-
-
+
+
+
+
+
+
+
-
-
-
-
+
-
-
-
+
-
-
+
+
+
+
+
+
+
-
HEK293s CB2 HEK293s
pERK 1/2
HA HA
